fig2

Figure 2. Percentage age of adverse events in patients using sofosbuvir (SOF) and daclatasvir (DAC) with or without ribavirin
Figure 2. Percentage age of adverse events in patients using sofosbuvir (SOF) and daclatasvir (DAC) with or without ribavirin
All published articles are preserved here permanently:
https://www.portico.org/publishers/oae/